Skip to main content
S&P 5007,656.98+0.86%DOW52,573.29+0.98%NASDAQ26,333.03+0.96%BTC$77,267.00+0.58%ETH$2,510.86+2.27%GOLD$4,390.00-0.39%OIL$99.99-2.43%
Smart Investors Daily
AM

NASDAQ · AMRN

Amarin Corporation plc

Healthcare · Biotechnology

$13.80

Down-$0.24 (-1.71%)

Updated Sep 13, 2026, 9:08 PM

SID Score

3.5/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
285.42M
P/E ratio
-147.97
Dividend yield
0.00%
52-week range
$12.96 – $17.25
Volume
49.37K
Avg. volume
93.27K

Price performance

AMRN price history

1M range · 19 trading sessions · Daily adjusted prices

AMRN closed at $13.80 after 19 trading sessions, down 1.50% for the selected period.

Last close
$13.80
Period change
-1.50%
Period low
$13.63
Period high
$14.39
Daily close
View OHLC price history
AMRN OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 11, 2026$14.09$14.10$13.68$13.8049.37K
Sep 10, 2026$14.27$14.298$13.895$14.0451.75K
Sep 9, 2026$14.17$14.395$14.07$14.3933.69K
Sep 8, 2026$13.52$14.30$13.19$14.2599.81K
Sep 4, 2026$13.67$13.85$13.5201$13.6380.56K
Sep 3, 2026$13.68$13.8699$13.60$13.7148.44K
Sep 2, 2026$13.88$14.02$13.68$13.7045.61K
Sep 1, 2026$13.81$14.1881$13.81$13.84539.94K
Aug 31, 2026$13.97$14.32$13.73$13.8840.87K
Aug 28, 2026$14.15$14.90$13.88$13.9778.2K
Aug 27, 2026$14.41$14.4284$13.80$14.0783.43K
Aug 26, 2026$14.17$15.245$14.11$14.375159.43K
Aug 25, 2026$14.01$14.43$13.905$14.15505.37K
Aug 24, 2026$14.09$14.10$13.81$13.84106.41K
Aug 21, 2026$14.04$14.225$14.02$14.0936.56K
Aug 20, 2026$14.22$14.355$14.05$14.0631.5K
Aug 19, 2026$14.29$14.55$14.0921$14.3859.91K
Aug 18, 2026$13.93$14.2336$13.90$14.1352.97K
Aug 17, 2026$13.92$14.17$13.90$14.0157.15K

Latest AMRN news

The latest Smart Investors Daily articles mentioning AMRN.

Stock researchCompany · Overview

AMRN research

Overview

Company profile and research snapshot.

Company profile

Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$2.17
Implied upside
—
Analysts
—
AMRN recent ratings
DateFirmRatingTarget
Aug 21, 2026JP MorganUnderweight—
Jun 25, 2025Goldman SachsSell—
Apr 17, 2025Goldman SachsSell—
Jun 20, 2024Cantor FitzgeraldOverweight—
Jun 18, 2024Cantor FitzgeraldOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Aug 31, 2026

Amarin Highlights New REDUCE-IT® and Mechanistic Data Presented at European Society of Cardiology (ESC) Congress 2026

Presentations Expand Understanding of Treatment Adherence, Long-Term Outcomes, Lipoprotein(a), Coagulation Biomarkers, and Potential Mechanisms of Eicosapentaenoic Acid (EPA) 2026 ESC/European Renal Association (ERA) Cardiovascular and Chronic Kidney Disease Guideline Further Reinforces the Clinical Evidence Supporting Icosapent Ethyl DUBLIN and BRIDGEWATER, N.J., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascula

Yahoo · Aug 28, 2026

New REDUCE-IT® Legacy Analysis Presented at European Society of Cardiology (ESC) Congress 2026 Suggests Persistent Cardiovascular Benefit Following Icosapent Ethyl Treatment Cessation in Adherent Patients

Data Supports Approximately 30% Relative Risk Reduction Among Highly Adherent Patients and Provides Evidence Consistent with a Potential Legacy Effect in Secondary Prevention Patients After Treatment DiscontinuationDUBLIN and BRIDGEWATER, N.J., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular disease worldwide, today highlighted a new post hoc analysis from the landmark REDUCE-IT® cardiovascular outcomes trial,

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By